Cargando…

Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis (i.e., nonalcoholic fatty liver [NAFL]) to nonalcoholic steatohepatitis (NASH), cirrhosis, and cancer. Currently, the driver for this progression is not fully understood; in particular, it is not known how NAFLD and its earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Hall, Zoe, Bond, Nicholas J., Ashmore, Tom, Sanders, Francis, Ament, Zsuzsanna, Wang, Xinzhu, Murray, Andrew J., Bellafante, Elena, Virtue, Sam, Vidal‐Puig, Antonio, Allison, Michael, Davies, Susan E., Koulman, Albert, Vacca, Michele, Griffin, Julian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396354/
https://www.ncbi.nlm.nih.gov/pubmed/27863448
http://dx.doi.org/10.1002/hep.28953
_version_ 1783230051994566656
author Hall, Zoe
Bond, Nicholas J.
Ashmore, Tom
Sanders, Francis
Ament, Zsuzsanna
Wang, Xinzhu
Murray, Andrew J.
Bellafante, Elena
Virtue, Sam
Vidal‐Puig, Antonio
Allison, Michael
Davies, Susan E.
Koulman, Albert
Vacca, Michele
Griffin, Julian L.
author_facet Hall, Zoe
Bond, Nicholas J.
Ashmore, Tom
Sanders, Francis
Ament, Zsuzsanna
Wang, Xinzhu
Murray, Andrew J.
Bellafante, Elena
Virtue, Sam
Vidal‐Puig, Antonio
Allison, Michael
Davies, Susan E.
Koulman, Albert
Vacca, Michele
Griffin, Julian L.
author_sort Hall, Zoe
collection PubMed
description Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis (i.e., nonalcoholic fatty liver [NAFL]) to nonalcoholic steatohepatitis (NASH), cirrhosis, and cancer. Currently, the driver for this progression is not fully understood; in particular, it is not known how NAFLD and its early progression affects the distribution of lipids in the liver, producing lipotoxicity and inflammation. In this study, we used dietary and genetic mouse models of NAFL and NASH and translated the results to humans by correlating the spatial distribution of lipids in liver tissue with disease progression using advanced mass spectrometry imaging technology. We identified several lipids with distinct zonal distributions in control and NAFL samples and observed partial to complete loss of lipid zonation in NASH. In addition, we found increased hepatic expression of genes associated with remodeling the phospholipid membrane, release of arachidonic acid (AA) from the membrane, and production of eicosanoid species that promote inflammation and cell injury. The results of our immunohistochemistry analyses suggest that the zonal location of remodeling enzyme LPCAT2 plays a role in the change in spatial distribution for AA‐containing lipids. This results in a cycle of AA‐enrichment in pericentral hepatocytes, membrane release of AA, and generation of proinflammatory eicosanoids and may account for increased oxidative damage in pericentral regions in NASH. Conclusion: NAFLD is associated not only with lipid enrichment, but also with zonal changes of specific lipids and their associated metabolic pathways. This may play a role in the heterogeneous development of NAFLD. (Hepatology 2017;65:1165‐1180)
format Online
Article
Text
id pubmed-5396354
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-53963542017-04-25 Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease Hall, Zoe Bond, Nicholas J. Ashmore, Tom Sanders, Francis Ament, Zsuzsanna Wang, Xinzhu Murray, Andrew J. Bellafante, Elena Virtue, Sam Vidal‐Puig, Antonio Allison, Michael Davies, Susan E. Koulman, Albert Vacca, Michele Griffin, Julian L. Hepatology Steatohepatitis/Metabolic Liver Disease Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis (i.e., nonalcoholic fatty liver [NAFL]) to nonalcoholic steatohepatitis (NASH), cirrhosis, and cancer. Currently, the driver for this progression is not fully understood; in particular, it is not known how NAFLD and its early progression affects the distribution of lipids in the liver, producing lipotoxicity and inflammation. In this study, we used dietary and genetic mouse models of NAFL and NASH and translated the results to humans by correlating the spatial distribution of lipids in liver tissue with disease progression using advanced mass spectrometry imaging technology. We identified several lipids with distinct zonal distributions in control and NAFL samples and observed partial to complete loss of lipid zonation in NASH. In addition, we found increased hepatic expression of genes associated with remodeling the phospholipid membrane, release of arachidonic acid (AA) from the membrane, and production of eicosanoid species that promote inflammation and cell injury. The results of our immunohistochemistry analyses suggest that the zonal location of remodeling enzyme LPCAT2 plays a role in the change in spatial distribution for AA‐containing lipids. This results in a cycle of AA‐enrichment in pericentral hepatocytes, membrane release of AA, and generation of proinflammatory eicosanoids and may account for increased oxidative damage in pericentral regions in NASH. Conclusion: NAFLD is associated not only with lipid enrichment, but also with zonal changes of specific lipids and their associated metabolic pathways. This may play a role in the heterogeneous development of NAFLD. (Hepatology 2017;65:1165‐1180) John Wiley and Sons Inc. 2017-02-06 2017-04 /pmc/articles/PMC5396354/ /pubmed/27863448 http://dx.doi.org/10.1002/hep.28953 Text en © 2016 by The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Steatohepatitis/Metabolic Liver Disease
Hall, Zoe
Bond, Nicholas J.
Ashmore, Tom
Sanders, Francis
Ament, Zsuzsanna
Wang, Xinzhu
Murray, Andrew J.
Bellafante, Elena
Virtue, Sam
Vidal‐Puig, Antonio
Allison, Michael
Davies, Susan E.
Koulman, Albert
Vacca, Michele
Griffin, Julian L.
Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
title Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
title_full Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
title_fullStr Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
title_full_unstemmed Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
title_short Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
title_sort lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
topic Steatohepatitis/Metabolic Liver Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396354/
https://www.ncbi.nlm.nih.gov/pubmed/27863448
http://dx.doi.org/10.1002/hep.28953
work_keys_str_mv AT hallzoe lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT bondnicholasj lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT ashmoretom lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT sandersfrancis lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT amentzsuzsanna lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT wangxinzhu lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT murrayandrewj lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT bellafanteelena lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT virtuesam lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT vidalpuigantonio lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT allisonmichael lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT daviessusane lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT koulmanalbert lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT vaccamichele lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease
AT griffinjulianl lipidzonationandphospholipidremodelinginnonalcoholicfattyliverdisease